Tags » Brilinta

Antidepressant Brintellix vs Anti-blood Clotting Medication Brilinta

The U.S. Food and Drug Administration is warning health care professionals and patients that reports of confusion between the antidepressant Brintellix and anti-blood clotting medication Brilinta have resulted in the wrong medication being prescribed or dispensed. 155 more words

Knowledge Areas

FDA Warns About Mixups Between Drugs With Similar Names

Here’s a scary thought: dangerous medication mixups could begin at your doctor’s office. The FDA put out a warning today that they’ve received reports of mixups between similarly-named drugs that do very different things. 253 more words


Long-term use of AZ' Brilinta, ticagrelor gets US priority review

An application to use AstraZeneca’s Brilinta to treat patients with a history of heart attack has been placed on a fast track regulatory pathway in the US, meaning that approval could be granted within just six months. 183 more words

Priority Review

Facile [3+2] cycloaddition continuous flow strategies to triazolopyrimidines

A recent example of reaction route scouting was published by a group at Northeastern University ( J Flow Chem 2014, Graham Jones et al) showing several critical factors going into the azide cycloaddition chemistry in forming a desired triazole. 443 more words

US Department Of Justice Ends Investigation Of AstraZenca Trial

AstraZeneca announced today that the US Department of Justice has ended its investigation into alleged misconduct associated with the pivotal PLATO trial. The company said it had fully cooperated with the investigation, which began in October of 2013. 10 more words

Policy & Ethics

UK Politician Urges More Use Of Ticagrelor To Preserve AstraZeneca Jobs In UK

Use it or lose it. A UK politician is urging the National Health Service (NHS) to increase use of the antiplatelet drug ticagrelor (trade name Brilinta in the US, Brilique and Possia in the EU) in order to prevent the loss of British jobs. 218 more words

Policy & Ethics

FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection

For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it had approved several generic versions of clopidogrel (Plavix), the antiplatelet drug that for many years was the second best-selling drug in the world.  570 more words

Policy & Ethics